Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 590-604

  Shea, Thomas C ^a   DiPersio, John F ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical applications; Cytokine induced mobilization; Effect of other cell adhesion molecules on HSC mobilization; Guidelines for "hard to mobilize" patient; High dose therapy and autologous PBHC supported transplantation and hematologic malignancies; Identifying optimal cell yield; Mobilization of autologous peripheral blood hematopoietic cells for cellular therapy; Role of proteases; Tumor contamination

Indexed keywords

EID: 84890670130     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch41     Document Type: Chapter

References (215)

1. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-77.
2. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58.
3. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D. Joint Accreditation Committee of the International Society for Cellular Therapy ISCT; European Group for Blood and Marrow Transplantation EBMT. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71-87.
4. Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Ann Rev Cell Dev Biol 2001; 17: 387-403.
5. Abrams RA, Glaubiger D, Appelbaum FR et al. Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: a case report. Blood 1980; 56: 516-20.
6. Kessigner A, Armitage JO, Landmark JD et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986; 14: 192-6.
7. Körbling M, Dörken B, Ho AD et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-32.
8. Juttner CA, To LB, Haylock DN et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61: 739-45.
9. To LB, Dyson PG, Juttner CA. Cell-dose effect in circulating stem-cell autografting. Lancet 1986; 2: 404-5.
10. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-9.
11. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocytemacrophage colony stimulating factor expands the circulating haemapoietic progenitor cells compartment in man. Lancet 1988; 1: 1194-8.
12. Gianni AM, Siena S, Bregni M et al. Granulocytemacrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-5.
13. Vogel W, Kunert C, Blumenstengel K, Fricke HG, Kath R, Sayer HG. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells. J Cancer Res Clin Oncol 1998; 124: 341-5.
14. To LB, Haylock DN, Dowse T et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994; 84: 2930-9.
15. Bensinger WI, Appelbaum FR, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547-55.
16. Bender JG, Lum L, Unverzagt KL et al. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 1994; 13: 479-85.
17. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-9.
18. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213-26.
19. Brecher ME, Sims L, Schmitz J, Shea T, Bentley SA. North American multicenter study on flow cytometric enumeration of CD34+ hematopoietic stem cells. J Hematother 1996; 5: 277-36.
20. Ruud E, Sharp JG. Report of the Tumor Evaluation Committee workshops at ISHAGE Cytotherapy 2002; 4: 79-81.
21. Pecora AL, Preti RA, Gleim GW et al. CD34+CD33-cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998; 16: 2093-104.
22. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colonystimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-19.
23. deBoer F, Drager AM, Van Haperen MJ et al. The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens. Br J Haematol 2000; 111: 1138-44.
24. Ninan MJ, Flowers CR, Roback JD, Arellano ML, Waller EK. Post-transplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2007; 13: 895-904.
25. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-94.
26. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-21.
27. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 intergrin. Proc Natl Acad Sci USA 1993; 90: 9374-8.
28. Avigdor A, Goichberg P, Shivtiel S et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004; 103: 2981-9.
29. Scott LM, Priestley GV, Papayannopoulou T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol 2003; 23: 9349-60.
30. Bullard DC, Kunkel EJ, Kubo H et al. Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and Pselectin double mutant mice. J Exp Med 1996; 183: 2329-36.
31. King AG, Horowitz D, Dillon SB et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. Blood 2001; 97: 1534-42.
32. Pruijt JF, Fibbe WE, Laterveer L et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A 1999; 96: 10863-68.
33. Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kitligand. Cell 2002; 109: 625-37.
34. Christopherson KW II, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates GCSF mobilization of mouse progenitor cells. Blood 2003a; 101: 4680-6.
35. Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal GCSF- induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol 2003; 31: 1126-34.
36. Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30.
37. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-18.
38. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 2002; 195: 1145-54.
39. Watanabe T, Dave B, Heimann DG, Lethaby E, Kessinger A, Talmadge JE. GM-CSF-mobilized peripheral blood CD34+ cells differ from steadystate bone marrow CD34+ cells in adhesion molecule expression. Bone Marrow Transplant 1997; 19: 1175-81.
40. Mohle R, Haas R, Hunstein W. Expression of adhesion molecules and c-kit on CD34+ hematopoietic progenitor cells: comparison of cytokinemobilized blood stem cells with normal bone marrow and peripheral blood. J Hematother 1993; 2: 483-9.
41. Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006; 108: 812-20.
42. Pelus LM, Horowitz D, Cooper SC, King AG. Peripheral blood stem cell mobilization. A role for CXC chemokines. Crit Rev Oncol Hematol 2002; 43: 257-75.
43. Kawabata K, Ujikawa M, Egawa T et al. A cellautonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci USA 1999; 96: 5663-7.
44. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10: 463-71.
45. Liles WC, Rodger E, Broxmeyer HE et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocytecolony- stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300.
46. Vroon A, Heijnan CJ, Baatgever R et al. GRK6 deficiency is associated with enhanced CXCR4- mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo. J Leukoc Biol 2004; 75: 698-704.
47. Semerad CL, Christopher MJ, Liu F et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106: 3020-7.
48. Levesque J-P, Leavesley DI, Niutta S et al. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 1995; 181: 1805-15.
49. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/ CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-96.
50. Levesque JP, Liu F, Simmons PJ, Betsuyaku T, Senior RM, Pham C, Link DC. Characterization of hematopoietic progenitor mobilization in proteasedeficient mice. Blood 2004; 104: 65-72.
51. Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17: 413-23.
52. Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colonystimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002; 30: 440-9.
53. Winkler IG, Hendy J, Coughlin P, Horvath A, Levesque JP. Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization. J Exp Med 2005; 201: 1077-88.
54. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule- 1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-97.
55. Papayannopoulou T, Priestley GV, Nakamoto B, Zafiropoulos V, Scott LM, Harlan JM. Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice. Blood 2001; 97: 1282-88.
56. Pilarski LM, Pruski E, Wizniak J et al. Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood 1999; 93: 2918-27.
57. Schmits R, Filmus J, Gerwin N et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 1997; 90: 2217-33.
58. Vermeulen M, Le Pesteur F, Gagnerault MC, Mary JY, Sainteny F, Lepault F. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood 1998; 92: 894-900.
59. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 1996; 84: 563-74.
60. Frenette PS, Weiss L. Sulfated glycans induce rapid hematopoietic progenitor cell mobilization: evidence for selectin-dependent and independent mechanisms. Blood 2000; 96: 2460-8.
61. Sweeney EA, Priestley GV, Nakamoto B, Collins RG, Beaudet AL, Papayannopoulou T. Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci USA 2000; 97: 6544-9.
62. Richard RE, Siritanaratkul N, Jonlin E, Skarpidi E, Heimfeld S, Blau CA. Collection of blood stem cells from patients with sickle cell anemia. Blood Cells Mol Dis 2005; 35: 384-8.
63. Statkute L, Verda L, Oyama Y et al. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 317-29.
64. Olsson-Stromberg U, Hoglund M, Bjorkholm M et al. Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy 601 G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma 2006; 47: 1768-73.
65. Brown RA, Adkins D, Khoury H et al. Long term follow-up of high-risk allogenic peripheral-blood stem-cell transplant recipients: graft-vs.-host disease and transplant-related mortality. J Clin Oncol 1999; 17: 806-12.
66. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-81.
67. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-72.
68. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98: 2900-8.
69. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human G-CSF on hematopoietic progenitor cells in cancer patients. Blood 1998; 72: 2074-81.
70. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-31.
71. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-5.
72. Nademanee A, Sniecinski I, Schmidt GM et al. High dose therapy followed by autologous peripheral- blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colonystimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-86.
73. AbdelkefiA, Maamar M, Torjman L et al. Prospective randomised comparison of the COBE spectra version 6 and haemonetics MCS(+) cell separators for hematopoietic progenitor cells leucapheresis in patients with multiple myeloma. J Clin Apher 2006; 21: 111-15.
74. Pettengell R, Morgenstern GR, Woll PJ et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770-7.
75. Ho AD, Gluck S, Germond C et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 7: 1738-44.
76. Haas R, Moos M, Karcher A et al. Sequential high-dose therapy with peripheral blood progenitor cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685-92.
77. Passos-Coelho JL, Braine HG, David JM et al. Predictive factors for peripheral-blood progenitorcell collection using a single large-volume apheresis after cyclophosphamide and granulocytemacrophage colony-stimulating factor mobilization. J Clin Oncol 1995; 13: 705-14.
78. Bandarenko N, Sims LC, Brecher ME. Circulating CD34+ cell counts are predictive of CD34+ peripheral blood progenitor cell yields [Letter]. Transfusion 1997; 37: 1218-20.
79. Fu P, Bagai RK, Meyerson H et al. Premobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant 2006; 38: 189-96.
80. Schroeder H, Kamperis K, Grunnet N, Hokland P. Prediction of target CD34 positive cells following leukoapheresis in children with neuroblastoma. Pediatr Blood Cancer 2006; 46: 786-92.
81. Desikan KR, Jagannath S, Siegel D et al. Collection of more hematopoietic progenitor cells with large volume apheresis in patients with multiple myeloma. Leuk Lymphoma 1998; 28: 501-8.
82. Moller AKH, Dickmeiss E, Geisler CH, Christensen LD. Recruitment of CD34+ cells during large-volume apheresis. A research report. J Hematother Stem Cell Res 2001; 10: 837-53.
83. Schwarer AP, Messino NM, Gibson M, Akers C, Taouk Y. A randomized trial of apheresis volumes, 7L versus 10L. An assessment of efficacy and patient tolerance. J Hematother Stem Cell Res 2000; 9: 269-74.
84. Demirer T, Dagli M, Ilhan O et al. A randomized trial of assessment of efficacy of apheresis volumes, 8 liters vs. 12 liters. Bone Marrow Transplant 2002; 29: 893-7.
85. Fontana S, Groebli R, Leibundgut K, Pabst T, Zwicky C, Taleghani BM. Progenitor cell recruitment during individualized high-flow, very-largevolume apheresis for autologous transplantation improves collection efficiency. Transfusion 2006; 46: 1408-16.
86. Reiffers J, Faberes C, Boiron JM et al. Peripheral blood progenitor cell transplantation of 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 1994; 3: 185-91.
87. Glaspy JA, Shpall EJ, LeMaistre CF et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939-51.
88. Beguin Y, Baudoux E, Sautois B et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells. Transfusion 1998; 38: 199-208.
89. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human G-CSF on hematopoietic progenitor cells in cancer patients. Blood 1998; 72: 2074-81.
90. Mahe B, Milpied N, Hermouet S et al. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma. Br J Haematol 1996; 92: 263-8.
91. Aglietta M, Piacibello W, Savavio F et al. Kinetics of human hemapoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989; 83: 551-7.
92. Haas R, Ho AD, Bredthauer U et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocytemacrophage colony-stimulating factor. Exp Hematol 1990; 18: 94-8.
93. Bishop MR, Anderson JR, Jackson JD et al. Highdose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610-16.
94. Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14: 913-18.
95. Sutherland HJ, Eaves CJ, Lansdorp PM et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994; 83: 3808-14.
96. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheralblood stem cells. J Clin Oncol 2000; 18: 43-53.
97. Englehardt M, Bertz H, Afting M, Waller CF, Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection. J Clin Oncol 1999; 17: 2160-72.
98. Demirer T, Ayli M, Ozcan M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colonystimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468-74.
99. Comenzo RL, Sanchorawala V, Fisher C et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104: 553-9.
100. Winter JN, Lazarus H, Rademaker A et al. Phase I/II study of combined granulocyte colonystimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-86.
101. Sohn SK, Kim JG, Seo KW et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81-6.
102. Lefrere F, Levy V, Makke J, Audat F, Cavazzana- Calvo M, Miclea JM. Successful peripheral blood stem cell harvesting with granulocyte colonystimulating factor alone after previous mobilization failure. Haematologica 2004; 89: 1532-4.
103. Kroger N, Renges H, Kruger W et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-5.
104. Komeno Y, Kanda Y, Hamaki T et al. Japan Hematology and Oncology Clinical Study Group. A randomized controlled trial to compare onceversus twice-daily filgrastim for mobilization of peripheral blood stem cells from healthy donors. Biol Blood Marrow Transplant 2006; 12: 408-13.
105. Kim S, Kim HJ, Park JS et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005; 84: 742-7.
106. Jackson JD, Yan Y, Brunda MJ, Kelsey LS, Talmadge JE. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995; 85: 2371-6.
107. Rosenfeld CS, Blowell M, LeVevre A, Taylor R, List A, Collins R. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and in combination with GM-CSF for G-CSF. Bone Marrow Transplant 1997; 17: 179-83.
108. Bodine DM, Seidel NE, Zsebo KM, Orlic D. In vivo administration of stem cell factor to mice increases the absolute number of pluripotent hematopoietic stem cells. Blood 1993; 82: 445-55.
109. Bochennek K, Andreas C, Margraf C et al. Hourly monitoring of circulating CD34+ cells to optimize timing of autologous apheresis in pediatric patients. Bone Marrow Transplant 2005; 36: 481-9.
110. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice [Review]. Leukemia 2002; 16: 1992-2003.
111. Burroughs L, Mielcarek M, Little M et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005; 106: 4002-8.
112. Larochelle A, Krouse A, Metzger M et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006; 107: 3772-8.
113. Hendrix CW, Collier AC, Lederman MM et al. AMD3100 HIV Study Group. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37: 1253-62.
114. Flomenberg N, Devine SM, DiPersio JF et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74.
115. Devine SM, Flomenberg N, Vesole DH et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-102.
116. Gazitt Y, Callander N, Freytes CO, Shaughnessy P, Tsai TW, Devore P. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GMCSF followed by G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res 2000; 9: 737-48.
117. Kroschinsky F, Holig K, Platzbecker U et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417-23.
118. Kopf B, De Giorgi U, Vertogen B et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006; 38: 407-12.
119. Bruns I, Steidl U, Kronenwett R et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patient with multiple myeloma. Transfusion 2006; 46: 180-5.
120. Steidl U, Fenk R, Bruns I et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-6.
121. Isidorins A, Tani M, Bonifazi F et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-31.
122. Shpall EJ, Wheeler CA, Turner SA et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2491-501.
123. Stiff P, Gingrich R, Luger S et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-81.
124. Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 2005; 36: 389-96.
125. da Silva MG, Pimentel P, Carvalhais A et al. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factorinduced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection. Bone Marrow Transplant 2004; 34: 683-91.
126. D'Hondt V, Guillaume T, Humblet Y et al. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study. Bone Marrow Transplant 1994; 13: 261-4.
127. Geissler K, Peschell C, Niederwieser D et al. Effect of interleukin-3 pretreatment on granulocyte/ macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells. Br J Haematol 1995; 91: 299-305.
128. Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standarddose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 1992; 10: 1452-9.
129. Kolbe K, Peschel C, Rupilius B et al. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients. Bone Marrow Transplant 1997; 20: 1027-32.
130. Goldman SC, Bracho F, Davenport V et al. Feasibility study of IL-11 and granulocyte colonystimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients. J Pediatr Hematol Oncol 2001; 23: 300-5.
131. Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C. Enhancement of the antitumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp Hematol 2000; 28: 96-103.
132. Sosman JA, Stiff P, Moss SM et al. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing highdose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol 2001; 19: 634-44.
133. Schiller G, Wong S, Lowe T et al. Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 2001; 15: 757-63.
134. Pelus LM, Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp Hematol 2006; 34: 1010-20.
135. Fukuda S, Bian H, King A, Pelus L. The chemokine GROß mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007; 110: 860-9.
136. Neben S, Marcus K, Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993; 81: 1960-7.
137. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 11: 1905-14.
138. Narayanasami U, Kanteti R, Morelli J et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-64.
139. Koc ON, Gerson SL, Cooper BW et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colonystimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824-30.
140. Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999; 23: 111-17.
141. Karanth M, Chakrabarti S, Lovell RA et al. A randomised study comparing peripheral blood progenitor mobilization using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Bone Marrow Transplant 2004; 34: 399-403.
142. Knudsen LM, Rasmussen T, Nikolaisen K, Johnsen HE. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Eur J Haematol 2001; 67: 289-95.
143. Krishnan A, Bhatia S, Slovak M et al. Predictors for therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-93.
144. Lefrere F, Zohar S, Bresson JL et al. A doubleblind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Haematologica 2006; 91: 550-3.
145. Dingli D, Nowakowski GS, Dispenzieri A et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384-8.
146. Fitoussi O, Perreau V, Boiron JM et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837-42.
147. Gojo I, Guo C, Sarkodee-Adoo C et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant 2004; 34: 69-76.
148. Reiser M, Josting A, Draube A et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999; 23: 1223-8.
149. Ashihara E, Shimazaki C, Okano A, Hatsuse M, Inaba T, Nakagawa M. Feasibility and efficacy of high-dose etoposide followed by low-dose G-CSF as a mobilization regimen in patients with non- Hodgkin's lymphoma. Haematologica 2000; 85: 1112-14.
150. Tarella C, Di Nicola M, Caracciolo D et al. Highdose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002; 30: 725-32.
151. Damon L, Rugo H, Tolaney S et al. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant 2006; 12: 316-24.
152. Jacoub JF, Suryadevara U, Pereyra V et al. Mobilization strategies for the collection of peripheral blood progenitor cells: results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006; 34: 1443-50.
153. Hart C, Blank C, Krause SW, Andreesen R, Hennemann B. Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide. Ann Hematol 2007; 86: 575-81.
154. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-85.
155. Petit J, Boque C, Cancelas JA et al. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilization regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leukemia Lymph 1999; 34: 119-27.
156. Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilization regimen for transplant-eligible patients with non- Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007; 136: 752-61.
157. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP + fixed dose GCSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006; 37: 277-82.
158. D'Sa S, Yong K, Kyriakou C et al. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. Br J Haematol 2004; 125: 756-65.
159. Mele A, Leopardi G, Sparaventi G et al. Mini-ICE effectively mobilizes peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. Eur J Haematol 2005; 74: 277-81.
160. Endo T, Sato N, Mogi Y et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 703-7.
161. Smardova L, Engert A, Haverkamp H et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colonystimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005; 46: 1017-22.
162. Lefrere F, Zohar S, Ghez D et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant 2006; 37: 725-9.
163. Hosing C, Saliba RM, Korbling M et al. Highdose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 1290-4.
164. Belhadj K, Delfau-Larue MH, Elgnaoui T et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol 2004; 15: 504-10.
165. Arcaini L, Orlandi E, Alessandrino EP et al. A model of in vivo purging with rituximab and highdose araC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004; 34: 175-9.
166. Hoerr AL, Gao F, Hidalgo J et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561-6.
167. van Heeckeren WJ, Vollweiler J, Fu P et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006; 132: 42-55.
168. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-8.
169. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-96.
170. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-8.
171. Moskowitz CH, Glassman JR, West D et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-16.
172. Weaver Ch, Zhen B, Buckner CD. Treatment of patients with malignant lymphoma with mini- BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant 1998; 21: 1169-70.
173. Nickenig C, Dreyling M, Hoster E et al. German Low-Grade Lymphoma Study Group. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas -results of a randomized comparison by the German Low- Grade Lymphoma Study Group. Ann Oncol 2007; 18: 136-42.
174. Perez-Calvo J, Fernandez O, Aristu JJ et al. A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients. Bone Marrow Transplant 2004; 33: 499-502.
175. Michallet M, Thiebaut A, Dreger P et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: 595-601.
176. Visani G, Lemoli RM, Tosi P et al. Fludarabinecontaining regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775-9.
177. Tournilhac O, Cazin B, Lepretre S et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-5.
178. Kobbe G, Sohngen D, Bauser U et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol 1999; 78: 456-62.
179. de la Rubia J, Blade J, Lahuerta JJ et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 2006; 91: 621-7.
180. Gupta S, Zhou P, Hassoun H et al. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone Marrow Transplant 2005; 35: 441-7.
181. Keane C, Gibbs S, Seymour JF et al. The Hyper- CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematol Oncol 2006; 24: 159-63.
182. Perry AR, Watts MJ, Peniket AM, Goldstone AH, Linch DC. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant 1998; 21: 1201-5.
183. Tarella C, Zallio F, Caracciolo D, Cherasco C, Bondesan P, Gavarotti P. Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells 1999; 17: 55-61.
184. Stiff PJ. Management strategies for the hard-tomobilize patient. Bone Marrow Transplant 1999; 23(Suppl 2): 29-33.
185. Bentley SA, Brecher ME, Powell E, Serody JS, Wiley JM, Shea TC. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients. Bone Marrow Transplant 1997; 19: 557-63.
186. Lie AKW, Hui CH, Rawling T et al. Granulocyte colony-stimulating factor (G-CSF) dosedependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant 1998; 22: 853-7.
187. Gazitt Y, Freytes C, Callander N et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8: 173-83.
188. Fraipont V, Sautois B, Baudoux E et al. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve suffi- cient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion 2000; 40: 339-47.
189. Mijovic A, Pagliuca A, Mufti GJ. The 'G-CSF test.' The response to a single dose of granulocyte colony-stimulating factor predicts mobilization of hemopoietic progenitors in patients with hematologic malignancies. Exp Hematol 1999; 27: 1204-9.
190. Brown RA, Adkins D, Goodnough LT et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3067-74.
191. Fruehauf S, Schmitt K, Veldwijk MR et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999; 105: 786-94.
192. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-40.
193. Passos Coelho JL, Ross AA, Kahn DJ et al. Similar breast cancer cell contamination of singleday peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 14: 2569-75.
194. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-19.
195. Tricot G, Gazitt Y, Leemhuis T et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998; 91: 4489-95.
196. Kruger W, Kroger N, Togel F et al. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colonystimulating factor mobilized stem cells. J Hematother Stem Cell Res 2001; 10: 303-7.
197. Bierman PJ, Sweetenham JW, Loberiza FR Jr et al. Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Syngeneic hematopoietic stemcell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation -The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744-53.
198. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-9.
199. Gianni AM, Magni M, Martelli M et al. Longterm remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (RHDS regimen). Blood 2003; 102: 749-55.
200. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729-35.
201. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34- positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
202. Verfaillie CM, Bhatia R, Steinbuch M et al. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood 1998; 92: 1820-31.
203. Stewart K, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression- free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-9.
204. Sheridan WP, Begley CG, To LB et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore haemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105-11.
205. Velders GA, Pruijt JF, Verzaal P et al. Enhancement of G-CSF-induced stem cell mobilization by antibodies against the b2 integrins LFA-1 and Mac-1. Blood 2002; 100: 327-33.
206. Molineux G, McCrea C, Yan XQ et al. Flt-3 ligand synergizes with granulocyte colonystimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997; 89: 3998-4004.
207. Brasel K, McKenna HJ, Charrier K, Morrissey PJ, Williams DE, Lyman SD. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997; 90: 3781-8.
208. Craddock CF, Nakamoto B, Andrews RG et al. Antibodies of VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90: 4779-88.
209. Gazitt Y, Shaughnessy P, Liu Q. Expression of adhesion molecules on CD34+ cells in peripheral blood of non-Hodgkin's lymphoma patients mobilized with different growth factors. Stem Cells 2001; 19: 134-43.
210. Ford CD, Greenwood J, Anderson J, Snow G, Petersen FB. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colonystimulating factor. Transfusion 2006; 46: 193-8.
211. Laterveer L, Lindley IJ, Hamilton MS, Willemze R, Fibbe WE. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood 1995; 85: 2269-75.
212. Laterveer L, Lindley IJ, Heemskerk DP et al. Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8. Blood 1996; 897: 781-8.
213. Carlo-Stella C, Di Nicola M, Longoni P et al. Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. Exp Hematol 2004; 32: 68-75.
214. Carlo-Stella C, Di Nicola M, Milani R et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colonystimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287-95.
215. Schwarzenberger P, Huang W, Oliver P et al. IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice. J Immunol 2001; 167: 2081-6.